Clinical Trials Browser

Breast Neoplasms

NCT07441460 2026-03-02

A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer

Phase 3 Not yet recruiting

1,800 enrolled

Breast

Resectable HER2-positive Breast Cancer

NCT07432178 2026-02-25

CDK4/6 Inhibitors Intensification for Chemotherapy Omission in Small Size High-risk ER-positive Breast Cancer（Cinnamon）

Phase 3 Not yet recruiting

2,288 enrolled

Breast

Breast Neoplasms

NCT07406542 2026-02-12

A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer

Phase 3 Not yet recruiting

400 enrolled

Breast

Breast Neoplasms, Recurrence

NCT07407517 2026-02-12

POLARIS

Phase 3 Not yet recruiting

904 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07385365 2026-02-11

A Study of Postoperative Regional Nodal Radiotherapy in Intermediate-risk Breast Cancer

Phase 3 Not yet recruiting

3,142 enrolled

Breast

Breast Neoplasms

NCT07400523 2026-02-10

Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy

Phase 3 Not yet recruiting

446 enrolled

Breast

Breast Neoplasms

NCT07393321 2026-02-06

A Phase III Clinical Trial of NTQ1062 in Combination With Fulvestrant for the Treatment of Advanced or Metastatic HR+/HER2- Breast Cancer

Phase 3 Not yet recruiting

210 enrolled

Breast

Breast Neoplasms

NCT07382687 2026-02-03

Famitinib Combined With SHR-A1811, Versus SHR-A1811 for CDK4/6 Inhibitors-resistent Advanced HR+/HER2- Breast Cancer With SNF4 Subtype

Phase 3 Not yet recruiting

248 enrolled

Breast

Breast Neoplasms

NCT07372144 2026-01-28

IARA

Phase 3 Not yet recruiting

227 enrolled

Breast

Breast Neoplasms

NCT07349069 2026-01-22

A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With High-Risk Early Breast Cancer

Phase 3 Not yet recruiting

4,800 enrolled

Breast

Breast Neoplasms

NCT07357298 2026-01-22

Phase III Trial of Brain MRI Surveillance in Stage IV Breast Cancer

Phase 3 Not yet recruiting

156 enrolled

Breast

Breast Neoplasms

NCT07354022 2026-01-21

A Study to Evluate Efficacy and Safety of HRS-8080 Combined With Dalpiciclib in Patients With Advanced or Metastatic Breast Cancer Resistant to Adjuvant Endocrine Therapy.

Phase 3 Not yet recruiting

912 enrolled

Breast

Breast Neoplasms

NCT07340658 2026-01-14

SIE-3

Phase 3 Not yet recruiting

300 enrolled

Breast

Breast Neoplasms

NCT07269691 2025-12-08

RaSOLVE: 125I Radioactive Seed Marking Effects on Pathological Complete Response Rate and Prognosis Post-Neoadjuvant Therapy in Early/Advanced Breast Cancer

Phase 3 Not yet recruiting

194 enrolled

Breast

Breast Neoplasms

NCT06787118 2025-12-02

PANDORA

Phase 3 Not yet recruiting

130 enrolled

Breast

Breast Neoplasms

NCT07242352 2025-11-21

ADAPTela

Phase 3 Not yet recruiting

1,520 enrolled

Breast

Breast Neoplasms

NCT07239271 2025-11-20

A Multicenter Phase III Clinical Study and Translational Research on Adaptive Neoadjuvant Therapy of De-escalation and Escalation for HER2-Positive Breast Cancer Based on Multi-Omics Response Evaluation Model

Phase 3 Not yet recruiting

2,000 enrolled

Breast

Patients With HER2-positive Breast Cancer (BC) Suitable for Neoadjuvant Therapy

NCT07213206 2025-10-08

Cinderella

Phase 3 Not yet recruiting

1,500 enrolled

Breast

Breast Neoplasms

NCT07106632 2025-09-29

OPTIMA-YOUNG

Phase 3 Not yet recruiting

3,380 enrolled

Breast

Breast Neoplasms

NCT07178730 2025-09-17

ADAPT-TN-IV

Phase 3 Not yet recruiting

765 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07153757 2025-09-04

DESCENT

Phase 3 Not yet recruiting

2,934 enrolled

Breast

Breast Cancer Early Stage Breast Cancer (Stage 1-3)

NCT06434077 2025-06-22

Clinical Trial Protocol: Randomized Placebo-Controlled Pilot Study of GcMAF (Soloways TM) in Patients With Metastatic Breast Cancer

Phase 3 Not yet recruiting

60 enrolled

Breast

Breast Neoplasms

NCT07021261 2025-06-13

Comparing UTD2 Combined With Capecitabine to Capecitabine as Adjuvant Therapy for Non-pCR TNBC Patients

Phase 3 Not yet recruiting

440 enrolled

Breast

Breast Neoplasms

NCT07005557 2025-06-05

SENIOR

Phase 3 Not yet recruiting

1,244 enrolled

Breast

Breast Neoplasms

NCT06996093 2025-05-30

Chemotherapy Omission in HR-positive/HER2-negative Breast Cancer With Lymph Node Negative Disease Receiving Adjuvant Endocrine Therapy and CDK4/6 Inhibitor

Phase 3 Not yet recruiting

2,508 enrolled

Breast

Breast Neoplasms

NCT06929325 2025-04-16

Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitors

Phase 3 Not yet recruiting

312 enrolled

Breast

Breast Neoplasms

NCT06811220 2025-02-06

The Effect of Oral Administration of Hesperidin and Diosmin in Reducing Paclitaxel-induced Peripheral Neuropathy in Breast Cancer Patients

Phase 3 Not yet recruiting

140 enrolled

Breast

Breast Neoplasms

NCT06774885 2025-01-14

ROLE OF FOLIC ACID IN THE MANAGEMENT OF ADJUVANT ENDOCRINE THERAPY-INDUCED HOT FLASHES IN BREAST CANCER PATIENTS

Phase 3 Not yet recruiting

120 enrolled

Breast

Breast Neoplasms, Hot Flashes

NCT06611514 2024-11-19

PROPOSE

Phase 3 Not yet recruiting

95 enrolled

Breast

Breast Neoplasms

NCT06407401 2024-11-05

Improvement of Quality of Life Through Supportive Treatments for Hormone Therapy - Related Symptoms in Patients With Early Breast Cancer

Phase 3 Not yet recruiting

399 enrolled

Breast

Breast Neoplasms, Musculoskeletal Pain, Drug-Related Side Effects and Adverse Reactions

NCT06561607 2024-08-20

A Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection Versus Investigator-Selected Chemotherapy in HER2 Low-Expressing Recurrent/Metastatic Breast Cancer

Phase 3 Not yet recruiting

542 enrolled

Breast

Breast Neoplasms

NCT06270355 2024-02-28

SMART

Phase 3 Not yet recruiting

70,000 enrolled

Breast

Breast Neoplasms

NCT05993559 2024-01-12

Necessity of Post-mastectomy Radiotherapy After Neoadjuvant Chemotherapy and Mastectomy

Phase 3 Not yet recruiting

1,314 enrolled

Breast

Breast Neoplasms

NCT05901935 2023-06-13

DP303c in Patients With HER2-positive Advanced Breast Cancer

Phase 3 Not yet recruiting

420 enrolled

Breast

HER2-positive Advanced Breast Cancer

NCT05889871 2023-06-05

A Randomized, Controlled, Open-label Clinical Trial of Adjuvant Intensive Therapy for HR+/ HER2-SNF4 Early Breast Cancer

Phase 3 Not yet recruiting

916 enrolled

Breast

HR+/HER2-breast Cancer

NCT05841381 2023-05-03

Adjuvant Study of Pyrotinib in Combination With Trastuzumab in HER2 Positive Invasive Breast Cancer

Phase 3 Not yet recruiting

876 enrolled

Breast

Breast Neoplasms

NCT05388500 2022-05-27

PHARE-C

Phase 3 Not yet recruiting

800 enrolled

Breast

HER2-positive Breast Cancer

NCT05172518 2021-12-29

Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast Cancer

Phase 3 Not yet recruiting

512 enrolled

Breast

Breast Neoplasms

NCT04973319 2021-07-22

Trastuzumab Combined With Pertuzumab for Adjuvant Treatment of Breast Cancer After Neoadjuvant Therapy

Phase 3 Not yet recruiting

450 enrolled

Breast

Breast Neoplasms

NCT04337658 2020-04-08

FAVOR

Phase 3 Not yet recruiting

493 enrolled

Breast

Breast Neoplasms

NCT04301739 2020-03-12

to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC)

Phase 3 Not yet recruiting

522 enrolled

Breast

Triple Negative Breast Neoplasms

Clinical Trials

YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer

A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer

CDK4/6 Inhibitors Intensification for Chemotherapy Omission in Small Size High-risk ER-positive Breast Cancer（Cinnamon）

A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer

POLARIS

A Study of Postoperative Regional Nodal Radiotherapy in Intermediate-risk Breast Cancer

Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy

A Phase III Clinical Trial of NTQ1062 in Combination With Fulvestrant for the Treatment of Advanced or Metastatic HR+/HER2- Breast Cancer

Famitinib Combined With SHR-A1811, Versus SHR-A1811 for CDK4/6 Inhibitors-resistent Advanced HR+/HER2- Breast Cancer With SNF4 Subtype

IARA

A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With High-Risk Early Breast Cancer

Phase III Trial of Brain MRI Surveillance in Stage IV Breast Cancer

A Study to Evluate Efficacy and Safety of HRS-8080 Combined With Dalpiciclib in Patients With Advanced or Metastatic Breast Cancer Resistant to Adjuvant Endocrine Therapy.

SIE-3

RaSOLVE: 125I Radioactive Seed Marking Effects on Pathological Complete Response Rate and Prognosis Post-Neoadjuvant Therapy in Early/Advanced Breast Cancer

PANDORA

ADAPTela

A Multicenter Phase III Clinical Study and Translational Research on Adaptive Neoadjuvant Therapy of De-escalation and Escalation for HER2-Positive Breast Cancer Based on Multi-Omics Response Evaluation Model

Cinderella

OPTIMA-YOUNG

ADAPT-TN-IV

DESCENT

Clinical Trial Protocol: Randomized Placebo-Controlled Pilot Study of GcMAF (Soloways TM) in Patients With Metastatic Breast Cancer

Comparing UTD2 Combined With Capecitabine to Capecitabine as Adjuvant Therapy for Non-pCR TNBC Patients

SENIOR

Chemotherapy Omission in HR-positive/HER2-negative Breast Cancer With Lymph Node Negative Disease Receiving Adjuvant Endocrine Therapy and CDK4/6 Inhibitor

Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitors

The Effect of Oral Administration of Hesperidin and Diosmin in Reducing Paclitaxel-induced Peripheral Neuropathy in Breast Cancer Patients

ROLE OF FOLIC ACID IN THE MANAGEMENT OF ADJUVANT ENDOCRINE THERAPY-INDUCED HOT FLASHES IN BREAST CANCER PATIENTS

PROPOSE

Improvement of Quality of Life Through Supportive Treatments for Hormone Therapy - Related Symptoms in Patients With Early Breast Cancer

A Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection Versus Investigator-Selected Chemotherapy in HER2 Low-Expressing Recurrent/Metastatic Breast Cancer

SMART

Necessity of Post-mastectomy Radiotherapy After Neoadjuvant Chemotherapy and Mastectomy

DP303c in Patients With HER2-positive Advanced Breast Cancer

A Randomized, Controlled, Open-label Clinical Trial of Adjuvant Intensive Therapy for HR+/ HER2-SNF4 Early Breast Cancer

Adjuvant Study of Pyrotinib in Combination With Trastuzumab in HER2 Positive Invasive Breast Cancer

PHARE-C

Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast Cancer

Trastuzumab Combined With Pertuzumab for Adjuvant Treatment of Breast Cancer After Neoadjuvant Therapy

FAVOR

to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC)